BACKGROUND: Pediatric rhabdomyosarcoma (RMS) is highly curable, however, cure may come with significant radiation related toxicity in developing tissues. Proton therapy (PT) can spare excess dose to normal structures, potentially reducing the incidence of adverse effects. METHODS: Between 2005 and 2012, 54 patients were enrolled on a prospective multi-institutional phase II trial using PT in pediatric RMS. As part of the protocol, intensity modulated radiation therapy (IMRT) plans were generated for comparison with clinical PT plans. RESULTS: Target coverage was comparable between PT and IMRT plans with a mean CTV V95 of 100% for both modalities (p=0.82). However, mean integral dose was 1.8 times higher for IMRT (range 1.0-4.9). By site, mean integral dose for IMRT was 1.8 times higher for H&N (p<0.01) and GU (p=0.02), 2.0 times higher for trunk/extremity (p<0.01), and 3.5 times higher for orbit (p<0.01) compared to PT. Significant sparing was seen with PT in 26 of 30 critical structures assessed for orbital, head and neck, pelvic, and trunk/extremity patients. CONCLUSIONS: Proton radiation lowers integral dose and improves normal tissue sparing when compared to IMRT for pediatric RMS. Correlation with clinical outcomes is necessary once mature long-term toxicity data are available.
BACKGROUND:Pediatric rhabdomyosarcoma (RMS) is highly curable, however, cure may come with significant radiation related toxicity in developing tissues. Proton therapy (PT) can spare excess dose to normal structures, potentially reducing the incidence of adverse effects. METHODS: Between 2005 and 2012, 54 patients were enrolled on a prospective multi-institutional phase II trial using PT in pediatric RMS. As part of the protocol, intensity modulated radiation therapy (IMRT) plans were generated for comparison with clinical PT plans. RESULTS: Target coverage was comparable between PT and IMRT plans with a mean CTV V95 of 100% for both modalities (p=0.82). However, mean integral dose was 1.8 times higher for IMRT (range 1.0-4.9). By site, mean integral dose for IMRT was 1.8 times higher for H&N (p<0.01) and GU (p=0.02), 2.0 times higher for trunk/extremity (p<0.01), and 3.5 times higher for orbit (p<0.01) compared to PT. Significant sparing was seen with PT in 26 of 30 critical structures assessed for orbital, head and neck, pelvic, and trunk/extremity patients. CONCLUSIONS: Proton radiation lowers integral dose and improves normal tissue sparing when compared to IMRT for pediatric RMS. Correlation with clinical outcomes is necessary once mature long-term toxicity data are available.
Authors: Harald Paganetti; Andrzej Niemierko; Marek Ancukiewicz; Leo E Gerweck; Michael Goitein; Jay S Loeffler; Herman D Suit Journal: Int J Radiat Oncol Biol Phys Date: 2002-06-01 Impact factor: 7.038
Authors: Damien C Weber; Alexei V Trofimov; Thomas F Delaney; Thomas Bortfeld Journal: Int J Radiat Oncol Biol Phys Date: 2004-04-01 Impact factor: 7.038
Authors: Adepitan A Owosho; SaeHee K Yom; Zhiqiang Han; Kevin Sine; Nancy Y Lee; Joseph M Huryn; Cherry L Estilo Journal: Oral Surg Oral Med Oral Pathol Oral Radiol Date: 2016-07-19
Authors: Martin T King; Laszlo Voros; Gil'ad N Cohen; Ryan M Lanning; Ian Ganly; Chibuzo C O'Suoji; Suzanne L Wolden Journal: Brachytherapy Date: 2016-08-12 Impact factor: 2.362
Authors: Natalie A Lockney; Danielle Novetsky Friedman; Leonard H Wexler; Charles A Sklar; Dana L Casey; Suzanne L Wolden Journal: Pediatr Blood Cancer Date: 2016-05-16 Impact factor: 3.167
Authors: Pierre Blanchard; Adam S Garden; G Brandon Gunn; David I Rosenthal; William H Morrison; Mike Hernandez; Joseph Crutison; Jack J Lee; Rong Ye; C David Fuller; Abdallah S R Mohamed; Kate A Hutcheson; Emma B Holliday; Nikhil G Thaker; Erich M Sturgis; Merrill S Kies; X Ronald Zhu; Radhe Mohan; Steven J Frank Journal: Radiother Oncol Date: 2016-06-21 Impact factor: 6.280
Authors: Adepitan A Owosho; Paul Brady; Suzanne L Wolden; Leonard H Wexler; Cristina R Antonescu; Joseph M Huryn; Cherry L Estilo Journal: Pediatr Hematol Oncol Date: 2016-09-30 Impact factor: 1.969
Authors: Stephen R Grant; David R Grosshans; Stephen D Bilton; John A Garcia; Mayank Amin; Mark S Chambers; Susan L McGovern; Mary F McAleer; William H Morrison; Winston W Huh; Michael E Kupferman; Anita Mahajan Journal: Radiother Oncol Date: 2015-07-28 Impact factor: 6.280
Authors: Torunn I Yock; Sundeep Bhat; Jackie Szymonifka; Beow Y Yeap; Jennifer Delahaye; Sarah S Donaldson; Shannon M MacDonald; Margaret B Pulsifer; Kristen S Hill; Thomas F DeLaney; David Ebb; Mary Huang; Nancy J Tarbell; Paul Graham Fisher; Karen A Kuhlthau Journal: Radiother Oncol Date: 2014-10-07 Impact factor: 6.280
Authors: Suzanne L Wolden; Elizabeth R Lyden; Carola A Arndt; Douglas S Hawkins; James R Anderson; David A Rodeberg; Carol D Morris; Sarah S Donaldson Journal: Int J Radiat Oncol Biol Phys Date: 2015-09-05 Impact factor: 7.038
Authors: Reinier C Hoogeveen; Marinka L F Hol; Bradley R Pieters; Brian V Balgobind; Erwin W E R Berkhout; Reineke A Schoot; Ludi E Smeele; Hans J H M Merks; Eddy A G Becking Journal: Dentomaxillofac Radiol Date: 2019-11-18 Impact factor: 2.419